Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT05525559
- Locations
- 🇺🇸
BUMC - Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT05522309
- Locations
- 🇨🇳
Beijing Tongren Hospital,CMU, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT05354843
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China
News
No news found